Aspen Neuroscience closed a $115 million Series C to accelerate clinical development of ANPD001 and expand manufacturing for autologous iPSC‑derived therapies. The company said proceeds will support ongoing Phase I/IIa dosing (including Cohort 3 commercial formulation), scale automated manufacturing and advance its pipeline of personalized cell therapies for neurological disorders. Aspen highlighted Fast Track designation from the FDA for ANPD001 and presented six‑month safety and efficacy data from early cohorts at recent meetings. The financing targets clinical and operational readiness to meet anticipated commercial demand while building quality controls for individualized cell products.